D. Boral Capital Begins Coverage on Checkpoint Therapeutics (NASDAQ:CKPT)

Equities research analysts at D. Boral Capital began coverage on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research note issued to investors on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. D. Boral Capital’s price objective would suggest a potential upside of 183.91% from the company’s current price.

Several other equities research analysts have also recently weighed in on the company. Lake Street Capital upped their target price on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 16th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a report on Monday, December 16th.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT opened at $3.17 on Monday. The stock has a market capitalization of $154.80 million, a P/E ratio of -1.72 and a beta of 1.36. The stock’s fifty day moving average is $3.63 and its 200 day moving average is $2.88. Checkpoint Therapeutics has a 52 week low of $1.38 and a 52 week high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its earnings results on Tuesday, November 12th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Equities research analysts forecast that Checkpoint Therapeutics will post -0.91 earnings per share for the current year.

Insider Buying and Selling

In other news, CEO James F. Oliviero III sold 220,230 shares of the business’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $3.38, for a total transaction of $744,377.40. Following the sale, the chief executive officer now directly owns 3,194,583 shares in the company, valued at approximately $10,797,690.54. The trade was a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO William Garrett Gray sold 268,432 shares of the company’s stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the transaction, the chief financial officer now directly owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. This represents a 20.63 % decrease in their position. The disclosure for this sale can be found here. 2.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Checkpoint Therapeutics

A number of institutional investors have recently added to or reduced their stakes in CKPT. Choreo LLC raised its stake in shares of Checkpoint Therapeutics by 12.2% during the second quarter. Choreo LLC now owns 65,002 shares of the company’s stock valued at $133,000 after acquiring an additional 7,080 shares during the last quarter. XTX Topco Ltd acquired a new stake in Checkpoint Therapeutics in the second quarter valued at $34,000. B. Riley Wealth Advisors Inc. raised its position in Checkpoint Therapeutics by 366.3% during the 2nd quarter. B. Riley Wealth Advisors Inc. now owns 229,200 shares of the company’s stock worth $493,000 after purchasing an additional 180,050 shares during the last quarter. PVG Asset Management Corp acquired a new position in Checkpoint Therapeutics during the 2nd quarter worth about $295,000. Finally, Magnus Financial Group LLC grew its position in shares of Checkpoint Therapeutics by 12.9% in the 3rd quarter. Magnus Financial Group LLC now owns 35,000 shares of the company’s stock valued at $78,000 after buying an additional 4,000 shares during the last quarter. 22.00% of the stock is owned by institutional investors.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.